WILEX is a biopharmaceutical company based in Munich and is listed at the Frankfurt Stock Exchange at the Regulated Market / Prime Standard. The Company was founded in 1997 by a team of physicians and oncologists from the Technical University of Munich.

WILEX’s mission is to develop drugs with a low side effect profile and targeted treatment of different types of cancer as well as diagnostic agents for specific detection of tumours.

The Company's product candidates are based on antibodies and small molecules. WILEX has an attractive product pipeline which includes both drug and diagnostic candidates: The substances RENCAREX® and REDECTANE® are currently undergoing a Phase III registration trial. MESUPRON® is in a Phase II programme in two indications.
A Phase I study with the MEK-inhibitor WX-554, which WILEX acquired under the terms of the strategic partnership with UCB, was started in November 2009. The first dose in man has been administered.
The other four oncological programmes from UCB are currently still in preclinical development.

Based on this pipeline WILEX aims within a few years to be able to finance its research and development programmes from its operating cash flow.